title: Baseline severity of sepsis in subjects of the prowess and the Kybersept clinical trials on endogenous anticoagulants.
authors.affiliation: Department of Internal Medicine, Central Hospital of Bolzano, Bolzano (BZ), Italy. Christian.Wiedermann@asbz.i
authors.forename: Christian J
authors.initials: CJ
authors.lastname: Wiedermann
authors.forename: Heinz-Otto
authors.initials: HO
authors.lastname: Keinecke
authors.forename: Mathias
authors.initials: M
authors.lastname: Jürs
authors.forename: Steve M
authors.initials: SM
authors.lastname: Opal
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D011486:Protein C / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality*; D012720:Severity of Illness Index; D015996:Survival Rate
chemical_list: D000925:Anticoagulants; D011486:Protein C; D011994:Recombinant Proteins